Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.
Palsonify, a once-daily oral SST2 agonist, offers a noninvasive alternative to monthly depot injections, long considered the standard medical therapy for acromegaly.
Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...
Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
The compounds have exploded in popularity, but big questions about safety and effectiveness are still unresolved.
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Growth-hormone (GH) secretion is reduced in obesity, but studies of GH therapy in obese individuals have produced conflicting results. A meta-analysis of studies on the effects of recombinant human GH ...
Swole — without the serious side effects. For generations, gym rats have turned to illicit steroid use for bigger muscles, despite the numerous side effects and dangerous risks, from roid rage and ...
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published ...
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results